Combined, these results suggest that aberrantly activated AMPK in MIF/D-DT-deficient cells [15] is not solely responsible for the increased p53 activation or the defective clonal proliferation phenotypes observed in MIF/D-DT-deficient lung adenocarcinoma cells. The gene discussed is TP53; the disease is lung adenocarcinoma.